Regeneron Gets Wall Street-Low Price Target. The Stock May Be Done Outperforming the Market.Barrons • 06/06/22
Regeneron (REGN) Down 1.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/03/22
Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaborationMarket Watch • 06/02/22
Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of CancerPRNewsWire • 06/02/22
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone PaymentGlobeNewsWire • 06/02/22
Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularisGlobeNewsWire • 05/31/22
FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo NodularisPRNewsWire • 05/31/22
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)Zacks Investment Research • 05/25/22
Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High CholesterolPRNewsWire • 05/21/22
Regeneron's Growth Set To Slow, But Could Outperform Downbeat Consensus ForecastsSeeking Alpha • 05/21/22
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitisGlobeNewsWire • 05/20/22
FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic EsophagitisPRNewsWire • 05/20/22
CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPIBusiness Wire • 05/17/22
Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics EntrepreneurPRNewsWire • 05/17/22
Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo® (cemiplimab) in KRAS-Driven TumorsGlobeNewsWire • 05/16/22